Insider Transactions in Q1 2025 at Collegium Pharmaceutical, Inc (COLL)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
977
-0.59%
|
$29,310
$30.0 P/Share
|
|
Mar 14
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,255
-1.78%
|
$67,650
$30.0 P/Share
|
|
Mar 11
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,445
-5.95%
|
$313,350
$30.01 P/Share
|
|
Mar 07
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,348
-1.63%
|
$70,440
$30.0 P/Share
|
|
Mar 07
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,504
-0.85%
|
$45,120
$30.0 P/Share
|
|
Mar 06
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
18,682
-6.53%
|
$560,460
$30.0 P/Share
|
|
Mar 06
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,949
-1.09%
|
$58,470
$30.0 P/Share
|
|
Mar 06
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
26,067
-19.42%
|
$729,876
$28.5 P/Share
|
|
Mar 05
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
20,000
-12.97%
|
$560,000
$28.03 P/Share
|
|
Mar 04
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
40,000
-20.6%
|
$1,120,000
$28.08 P/Share
|
|
Mar 04
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+17.08%
|
$960,000
$24.03 P/Share
|
|
Feb 10
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
30,426
-7.47%
|
$912,780
$30.52 P/Share
|
|
Feb 10
2025
|
Colleen Tupper EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
78,725
+16.74%
|
-
|
|
Feb 10
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,623
-8.64%
|
$888,690
$30.52 P/Share
|
|
Feb 10
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,427
+17.97%
|
-
|
|
Feb 10
2025
|
Thomas B Smith EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,897
-3.19%
|
$176,910
$30.52 P/Share
|
|
Feb 10
2025
|
Thomas B Smith EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,075
+16.51%
|
-
|
|
Feb 10
2025
|
Michael Thomas Heffernan Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,820
+8.74%
|
-
|
|
Feb 10
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
34,975
-9.61%
|
$1,049,250
$30.52 P/Share
|
|
Feb 10
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
69,995
+16.84%
|
-
|
|
Feb 04
2025
|
Nancy Lurker Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,726
+50.0%
|
-
|
|
Jan 10
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
27,500
-9.73%
|
$907,500
$33.25 P/Share
|
|
Jan 10
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
27,500
+15.79%
|
$577,500
$21.34 P/Share
|